VictorYoussefYazbeckMD, MS

Hematologic Oncology

Associate Professor, Internal Medicine, Virginia Commonwealth University

Dr. Yazbeck is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
1250 E Marshall St
Dept of Internal Medicinehematologyoncology
Richmond, VA 23298
Phone+1 804-828-7999

Fax+1 804-828-5941

PubMed

Feasibility and preliminary efficacy of a physical activity intervention in adults with lymphoma undergoing treatment.
Juliana V Costa, Alexander R Lucas, Shannon L Mihalko, Peter H Brubaker, Alexandra Marshall
Pilot and Feasibility Studies. 2025-01-14
New and developing first line pharmacotherapies for treating non-Hodgkin lymphoma.
Bruce Hough, Olga Lytvynova, Ariel Sindel, Patrick Willard, Victor Yazbeck
Expert Opinion on Pharmacotherapy. 2024-08-01
1 citations
Advances in Hodgkin's lymphoma pharmacotherapy: a focus on histone deacetylase inhibitors.
Thuy Ho, Cara Coleman, Palak Shah, Victor Yazbeck
Expert Opinion on Pharmacotherapy. 2023-06-02

Abstracts/Posters

Phase 2 Study of Frontline Brentuximab Vedotin Plus Nivolumab in Patients with Hodgkin Lymphoma Aged _60 YearsClinically Relevant Abstract
Victor Yazbeck, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Brentuximab Vedotin in Front-Line Therapy of Hodgkin Lymphoma (HL) and CD30-Expressing Peripheral T-Cell Lymphoma (PTCL) in Adults Age 60 and Above
Victor Yazbeck, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Primary Ocular Lymphoma: A SEER Database Analysis of Patterns of Involvement and Outcomes
Victor Yazbeck, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019